3q7b Citations

Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression.

Proc Natl Acad Sci U S A 108 2396-401 (2011)
Cited: 184 times
EuropePMC logo PMID: 21262835

Abstract

Lassa fever virus, a member of the family Arenaviridae, is a highly endemic category A pathogen that causes 300,000-500,000 infections per year in Western Africa. The arenaviral nucleoprotein NP has been implicated in suppression of the host innate immune system, but the mechanism by which this occurs has remained elusive. Here we present the crystal structure at 1.5 Å of the immunosuppressive C-terminal portion of Lassa virus NP and illustrate that, unexpectedly, its 3D fold closely mimics that of the DEDDh family of exonucleases. Accompanying biochemical experiments illustrate that NP indeed has a previously unknown, bona fide exonuclease activity, with strict specificity for double-stranded RNA substrates. We further demonstrate that this exonuclease activity is essential for the ability of NP to suppress translocation of IFN regulatory factor 3 and block activation of the innate immune system. Thus, the nucleoprotein is a viral exonuclease with anti-immune activity, and this work provides a unique opportunity to combat arenaviral infections.

Reviews - 3q7b mentioned but not cited (1)

  1. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Hastie KM, Bale S, Kimberlin CR, Saphire EO. Curr Opin Virol 2 151-156 (2012)

Articles - 3q7b mentioned but not cited (2)



Reviews citing this publication (67)

  1. Nucleoproteins and nucleocapsids of negative-strand RNA viruses. Ruigrok RW, Crépin T, Kolakofsky D. Curr. Opin. Microbiol. 14 504-510 (2011)
  2. Conventional and unconventional mechanisms for capping viral mRNA. Decroly E, Ferron F, Lescar J, Canard B. Nat. Rev. Microbiol. 10 51-65 (2011)
  3. Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5. Reikine S, Nguyen JB, Modis Y. Front Immunol 5 342 (2014)
  4. Viral evasion of intracellular DNA and RNA sensing. Chan YK, Gack MU. Nat. Rev. Microbiol. 14 360-373 (2016)
  5. Recent advances in understanding viral evasion of type I interferon. Taylor KE, Mossman KL. Immunology 138 190-197 (2013)
  6. Ribonuclease III mechanisms of double-stranded RNA cleavage. Nicholson AW. Wiley Interdiscip Rev RNA 5 31-48 (2014)
  7. Current progress in antiviral strategies. Lou Z, Sun Y, Rao Z. Trends Pharmacol. Sci. 35 86-102 (2014)
  8. Emerging virus diseases: can we ever expect the unexpected? Howard CR, Fletcher NF. Emerg Microbes Infect 1 e46 (2012)
  9. The polymerase of negative-stranded RNA viruses. Morin B, Kranzusch PJ, Rahmeh AA, Whelan SP. Curr Opin Virol 3 103-110 (2013)
  10. Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Zinzula L, Tramontano E. Antiviral Res. 100 615-635 (2013)
  11. Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses. Zhou H, Sun Y, Guo Y, Lou Z. Trends Microbiol. 21 475-484 (2013)
  12. Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections. McLay L, Liang Y, Ly H. J. Gen. Virol. 95 1-15 (2014)
  13. Multifunctional nature of the arenavirus RING finger protein Z. Fehling SK, Lennartz F, Strecker T. Viruses 4 2973-3011 (2012)
  14. Advanced vaccine candidates for Lassa fever. Lukashevich IS. Viruses 4 2514-2557 (2012)
  15. Global virus outbreaks: Interferons as 1st responders. Wang BX, Fish EN. Semin Immunol 43 101300 (2019)
  16. Interplay between viruses and host mRNA degradation. Narayanan K, Makino S. Biochim. Biophys. Acta 1829 732-741 (2013)
  17. Arenavirus variations due to host-specific adaptation. Zapata JC, Salvato MS. Viruses 5 241-278 (2013)
  18. Immune responses and Lassa virus infection. Russier M, Pannetier D, Baize S. Viruses 4 2766-2785 (2012)
  19. Segmented negative strand RNA virus nucleoprotein structure. Reguera J, Cusack S, Kolakofsky D. Curr Opin Virol 5 7-15 (2014)
  20. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. Olschläger S, Flatz L. PLoS Pathog. 9 e1003212 (2013)
  21. Sensing microbial RNA in the cytosol. Vabret N, Blander JM. Front Immunol 4 468 (2013)
  22. Strategies for viral RNA stability: live long and prosper. Dickson AM, Wilusz J. Trends Genet. 27 286-293 (2011)
  23. The molecular biology of nairoviruses, an emerging group of tick-borne arboviruses. Lasecka L, Baron MD. Arch. Virol. 159 1249-1265 (2014)
  24. A versatile building block: the structures and functions of negative-sense single-stranded RNA virus nucleocapsid proteins. Sun Y, Guo Y, Lou Z. Protein Cell 3 893-902 (2012)
  25. Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis. Shao J, Liang Y, Ly H. Pathogens 4 283-306 (2015)
  26. Innate immune response to arenaviral infection: a focus on the highly pathogenic New World hemorrhagic arenaviruses. Koma T, Huang C, Kolokoltsova OA, Brasier AR, Paessler S. J. Mol. Biol. 425 4893-4903 (2013)
  27. SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, Canard B. Antiviral Res. 101 122-130 (2014)
  28. Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever. McLay L, Ansari A, Liang Y, Ly H. Antiviral Res. 97 81-92 (2013)
  29. RIG-I-like receptors and negative-strand RNA viruses: RLRly bird catches some worms. Weber M, Weber F. Cytokine Growth Factor Rev. 25 621-628 (2014)
  30. An evolving arsenal: viral RNA detection by RIG-I-like receptors. Fitzgerald ME, Rawling DC, Vela A, Pyle AM. Curr. Opin. Microbiol. 20 76-81 (2014)
  31. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Sevajol M, Subissi L, Decroly E, Canard B, Imbert I. Virus Res. 194 90-99 (2014)
  32. The role of innate immunity in conditioning mosquito susceptibility to West Nile virus. Prasad AN, Brackney DE, Ebel GD. Viruses 5 3142-3170 (2013)
  33. Molecular pathogenesis of viral hemorrhagic fever. Basler CF. Semin Immunopathol 39 551-561 (2017)
  34. Segmented negative-strand RNA viruses and RIG-I: divide (your genome) and rule. Weber M, Weber F. Curr. Opin. Microbiol. 20 96-102 (2014)
  35. Arenavirus Quasispecies and Their Biological Implications. Grande-Pérez A, Martin V, Moreno H, de la Torre JC. Curr Top Microbiol Immunol 392 231-276 (2016)
  36. Novel paradigms of innate immune sensing of viral infections. Hare D, Mossman KL. Cytokine 63 219-224 (2013)
  37. Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Radoshitzky SR, Kuhn JH, de Kok-Mercado F, Jahrling PB, Bavari S. Expert Opin Drug Discov 7 613-632 (2012)
  38. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense? De Groot AS, Einck L, Moise L, Chambers M, Ballantyne J, Malone RW, Ardito M, Martin W. Hum Vaccin Immunother 9 1877-1884 (2013)
  39. Improving the Breadth of the Host's Immune Response to Lassa Virus. Zapata JC, Medina-Moreno S, Guzmán-Cardozo C, Salvato MS. Pathogens 7 (2018)
  40. New World Arenavirus Biology. Sarute N, Ross SR. Annu Rev Virol 4 141-158 (2017)
  41. Novel drug discovery approaches for treating arenavirus infections. Pasquato A, Kunz S. Expert Opin Drug Discov 11 383-393 (2016)
  42. Current drug discovery strategies against arenavirus infections. Pasquato A, Burri DJ, Kunz S. Expert Rev Anti Infect Ther 10 1297-1309 (2012)
  43. Host Cell Restriction Factors of Bunyaviruses and Viral Countermeasures. Lerolle S, Freitas N, Cosset FL, Legros V. Viruses 13 784 (2021)
  44. Differential Immune Responses to Hemorrhagic Fever-Causing Arenaviruses. Mantlo E, Paessler S, Huang C. Vaccines (Basel) 7 (2019)
  45. Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. Brisse ME, Ly H. Front Immunol 10 372 (2019)
  46. Lassa fever - the road ahead. Garry RF. Nat Rev Microbiol 21 87-96 (2023)
  47. Nucleocapsid proteins: roles beyond viral RNA packaging. Ding B, Qin Y, Chen M. Wiley Interdiscip Rev RNA 7 213-226 (2016)
  48. Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments. Murphy HL, Ly H. Virulence 12 2989-3014 (2021)
  49. Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines. Murphy H, Ly H. Vaccines (Basel) 10 1668 (2022)
  50. Viral evasion of the interferon response at a glance. Zhu J, Chiang C, Gack MU. J Cell Sci 136 jcs260682 (2023)
  51. Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5. Brisse M, Ly H. Front Immunol 10 1586 (2019)
  52. Distinct Molecular Mechanisms of Host Immune Response Modulation by Arenavirus NP and Z Proteins. Stott RJ, Strecker T, Foster TL. Viruses 12 (2020)
  53. Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion. Pleet ML, DeMarino C, Stonier SW, Dye JM, Jacobson S, Aman MJ, Kashanchi F. Viruses 11 (2019)
  54. Minding the message: tactics controlling RNA decay, modification, and translation in virus-infected cells. Burgess HM, Vink EI, Mohr I. Genes Dev 36 108-132 (2022)
  55. Negative and ambisense RNA virus ribonucleocapsids: more than protective armor. Sabsay KR, Te Velthuis AJW. Microbiol Mol Biol Rev 87 e0008223 (2023)
  56. Progress in Anti-Mammarenavirus Drug Development. Kim YJ, Venturini V, de la Torre JC. Viruses 13 1187 (2021)
  57. Protection of eIF2B from inhibitory phosphorylated eIF2: A viral strategy to maintain mRNA translation during the PKR-triggered integrated stress response. Ito T, Wuerth JD, Weber F. J Biol Chem 299 105287 (2023)
  58. Replication of the coronavirus genome: A paradox among positive-strand RNA viruses. Grellet E, L'Hôte I, Goulet A, Imbert I. J Biol Chem 298 101923 (2022)
  59. Structural and molecular biology of Sabiá virus. Bezerra EH, Melo-Hanchuk TD, Marques RE. Exp Biol Med (Maywood) 248 1624-1634 (2023)
  60. Structural biology of SARS-CoV-2: open the door for novel therapies. Yan W, Zheng Y, Zeng X, He B, Cheng W. Signal Transduct Target Ther 7 26 (2022)
  61. The Activated Macrophage - A Tough Fortress for Virus Invasion: How Viruses Strike Back. Banete A, Barilo J, Whittaker R, Basta S. Front Microbiol 12 803427 (2021)
  62. The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity. Ogando NS, Ferron F, Decroly E, Canard B, Posthuma CC, Snijder EJ. Front Microbiol 10 1813 (2019)
  63. The Innate Antiviral Response in Animals: An Evolutionary Perspective from Flagellates to Humans. Majzoub K, Wrensch F, Baumert TF. Viruses 11 (2019)
  64. The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid. Šantak M, Matić Z. Viruses 14 521 (2022)
  65. The Virus-Host Interplay in Junín Mammarenavirus Infection. Gallo GL, López N, Loureiro ME. Viruses 14 1134 (2022)
  66. The mechanism of genome replication and transcription in bunyaviruses. Malet H, Williams HM, Cusack S, Rosenthal M. PLoS Pathog 19 e1011060 (2023)
  67. Viral pathogen-induced mechanisms to antagonize mammalian interferon (IFN) signaling pathway. Rojas JM, Alejo A, Martín V, Sevilla N. Cell Mol Life Sci 78 1423-1444 (2021)

Articles citing this publication (114)